Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04328077 · ClinicalTrials.gov registry record · Phase 2
LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Terns.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT04328077 is a Phase 2 study that has completed, run by Terns. The registered enrollment target is 101 participants.
The verdict
NCT04328077, a Phase 2 study, has completed, sponsored by Terns.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of TERN-101 in non-cirrhotic NASH patients.
Interventions
- OTHER Placebo
- DRUG TERN-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2020-06-18 |
| Est. Completion | 2021-05-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04328077
The ClinicalTrials.gov registry entry for NCT04328077 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Terns, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04328077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04328077 about?
NCT04328077 is a clinical study titled "LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)". This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of TERN-101 in non-cirrhotic NASH patients.
What is the current status of trial NCT04328077?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2020-06-18. Estimated completion is 2021-05-19.
What interventions are being tested in trial NCT04328077?
The interventions under investigation include: Placebo (OTHER), TERN-101 (DRUG).
Who is sponsoring clinical trial NCT04328077?
This trial is sponsored by Terns, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.